Recently, OPLAH was identified as one of the biomarkers that have been patented for the diagnosis of lung cancer (patent number: US 11028447 B2) [61] and CRC (patent number: US 11078539 B2) [62]. Here, OPLAH is linked to colorectal carcinoma.